You think Bristol Myers buying RayzeBio for USD$4.1 billion (AUD$6.16B) make TLX look cheap at market cap of AUD$6.3B (including the 17m shares for Nasdaq). Comparing the pipeline of drugs between the 2 companies are miles ahead. RayzeBio seems to only have 4 pipelines based on (https://rayzebio.com/pipeline/pipeline-overview/). You would think TLX is worth at least double what it is now.
News: TLX Telix Pharmaceuticals Aims Up To $4.17 Bln Valuation In US IPO, page-23
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.45 |
Change
0.520(2.48%) |
Mkt cap ! $7.178B | |||
| Open | High | Low | Value | Volume |
| $20.83 | $21.50 | $20.80 | $17.54M | 824.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2037 | $21.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.50 | 12320 | 5 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| TLX (ASX) Chart |